lilly glp-1 drugs Eli Gets Speedy FDA Nod for Oral Drug, a Competitor to New Novo Nordisk Pill Eli Lilly's oral GLP-1 pill

News provided by Ro Apr 09, 2026, 07:15 ET Foundayo gives patients a new once daily pill option and expands Ro's comprehensive weight loss formulary NEW YORK, April 9, 2026 /PRNewswire/ -- Ro, the leading direct-to-patient healthcare company, today announced eligible patients can now access Foundayo (orforglipron) Eli Lilly Company's newest oral GLP-1 innovation on the Ro platform, adding to Ro's already comprehensive formulary of FDA-approved GLP-1s

BPC-157 has been shown in animal models to adhere to the metabolic process of standard peptide-based drugs, suggesting that injections are the most bioavailable route of delivery

It is 100% safe and can be used by adults of all ages

And for many people, this phase works temporarily